Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2812848 | 0.83 | TSHR (0.51) | HPGDPKMKDM4EALDH1A1TSHR | |
| SCHEMBL6764380 | 0.83 | POLB (0.45) | HPGDPKMPOLBKDM4EALDH1A1 | |
| SCHEMBL6614810 | 0.80 | POLB (0.49) | HPGDPOLBKDM4EALDH1A1TSHR | |
| SCHEMBL10020214 | 0.74 | HPGD (0.79) | HPGDPOLBKDM4EALDH1A1HSD17B10 | |
| SCHEMBL2385706 | 0.74 | HPGD (0.64) | HPGDPOLBKDM4EALDH1A1ALOX15 | |
| SCHEMBL14938127 | 0.71 | ALOX15 (0.51) | HPGDPKMPOLBKDM4EALDH1A1 | |
| SCHEMBL2120631 | 0.70 | HPGD (0.68) | HPGDKDM4EALDH1A1HSD17B10TMEM97 | |
| SCHEMBL4490802 | 0.70 | — | — | |
| SCHEMBL14947438 | 0.70 | HPGD (0.67) | HPGDPOLBKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8411545 | 0.69 | HPGD (0.70) | HPGDKDM4EALDH1A1HSD17B10TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | HPGD 125/4885PKM 2951/4885POLB 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.